ONCAlert | Upfront Therapy for mRCC
Targeted Therapies introduces Investigator Perspectives, a video editorial series featuring thought leaders who provide expert perspectives on the latest advances in cancer care.
Select a Topic: – Select a topic –
Bladder Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Follicular Lymphoma
General Cancer
Kidney Cancer
Lung Cancer
Multiple Myeloma
Prostate Cancer
Skin Cancer
Browse by Series: – Select a Series –
Reducing Early Disease Progression in Follicular Lymphoma
Advances in Metastatic Castration-Sensitive Prostate Cancer
Addressing Unmet Needs in HER2-Positive Metastatic Breast Cancer
Daratumumab as Frontline Treatment for Multiple Myeloma
Novel IL-2 Based Combinations for Bladder Cancer
Real-World Data for Chemotherapy Treatment in Metastatic Triple-Negative Breast Cancer
Treatment Options for Stage III Unresectable NSCLC After Chemoradiotherapy
New Immunotherapeutic Agents Broaden Treatment Options for Chronic Lymphocytic Leukemia
PI3K Inhibitors in R/R Follicular Lymphoma
Treatment Options for Recurrent Metastatic Triple-Negative Breast Cancer
SIRT for Nonresectable CRC With Liver Metastases
Systemic Treatment of Metastatic Cutaneous Squamous Cell Carcinoma
Evolving NSCLC Treatment Paradigm
Upfront Therapy for mRCC
NKTR-214 & Nivolumab: Synergistic Activity Across Tumor Types
Endocrine Therapy for HR+ Metastatic Breast Cancer
PARP Inhibitors in Ovarian Cancer
Changing Treatment Landscape in Nonmetastatic CRPC
Immunotherapy in Unresectable Locally Advanced NSCLC
Treatment of Newly Diagnosed Advanced Kidney Cancer
Immunotherapy Use in Newly Diagnosed NSCLC
IMiD Sequencing in Multiple Myeloma
